{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:58:33Z","timestamp":1777503513573,"version":"3.51.4"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To evaluate whether there was a change in prevalence of human papillomavirus (HPV) in the United States correlated with the introduction of HPV vaccines in both vaccinated and unvaccinated women.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>We performed a retrospective review of prevalence data for women aged 18\u201329 years living in the United States using the National Health and Nutrition Examination Surveys, which is an ongoing series of cross-sectional surveys. Participants provided responses to standardized questions and self-collected cervicovaginal swabs in which a Linear Array HPV Assay was used to determine HPV prevalence. A total of 783 women from the prevaccine era (2003\u20132004) and 1,526 from the postvaccine era (2007\u20132012) were analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>Among women aged 18\u201329 years, the prevalence of vaccine-type HPV declined among women receiving one or more doses of vaccine (<jats:italic toggle=\"yes\">P<\/jats:italic>=.003): 10.1% (95% confidence interval [CI] 7.1\u201313.8%) in the prevaccine era to 4.2% (95% CI 3.3\u201310.9%) in the postvaccine era. There was no change in prevalence of nonvaccine-type HPV among women receiving one or more doses of vaccine (<jats:italic toggle=\"yes\">P<\/jats:italic>&gt;.05). There was also no change in prevalence of vaccine-type HPV among unvaccinated women from the prevaccine era 10.1% (95% CI 7.1\u201313.8%) to 8.8% (95% CI 5.6\u201312.9%) in the postvaccine era (<jats:italic toggle=\"yes\">P<\/jats:italic>=.4). Vaccine coverage increased to 31.5% of eligible women aged 18\u201329 years as of 2011\u20132012.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>Six years after introduction of HPV vaccination in the United States, there has been a decrease in the prevalence of vaccine-type HPV among women correlated with receiving one or more vaccine doses with no change in nonvaccine-type HPV. Furthermore, there has been no change in prevalence of vaccine-type HPV among unvaccinated women.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000001760","type":"journal-article","created":{"date-parts":[[2016,11,8]],"date-time":"2016-11-08T13:10:25Z","timestamp":1478610625000},"page":"1241-1247","source":"Crossref","is-referenced-by-count":11,"title":["Prevalence of Human Papillomavirus in Self-Collected Cervicovaginal Swabs in Young Women in the United States Between 2003 and 2012"],"prefix":"10.1097","volume":"128","author":[{"given":"Christopher M.","family":"Tarney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Klaric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Beltran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Pagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmine","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230711","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ygyno.2006.07.022","article-title":"Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists","volume":"102","author":"Collins","year":"2006","journal-title":"Gynecol Oncol"},{"key":"R2-20230711","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ygyno.2013.05.033","article-title":"HPV vaccine cross-protection: highlights on additional clinical benefit","volume":"130","author":"De Vincenzo","year":"2013","journal-title":"Gynecol Oncol"},{"key":"R3-20230711","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/infdis\/jit192","article-title":"Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003\u20132010","volume":"208","author":"Markowitz","year":"2013","journal-title":"J Infect Dis"},{"key":"R4-20230711","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16\u201326 years","volume":"199","author":"Brown","year":"2009","journal-title":"J Infect Dis"},{"key":"R5-20230711","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol"},{"key":"R6-20230711","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(14)71073-4","article-title":"Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis","volume":"15","author":"Drolet","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"R7-20230711","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S1473-3099(14)70841-2","article-title":"Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study","volume":"14","author":"Tabrizi","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"R8-20230711","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.297.8.813","article-title":"Prevalence of HPV infection among females in the United States","volume":"297","author":"Dunne","year":"2007","journal-title":"JAMA"},{"key":"R9-20230711","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ijid.2015.01.010","article-title":"Is vaccine type seropositivity a marker for human papillomavirus vaccination? National Health and Nutrition Examination Survey, 2003\u20132010","volume":"33","author":"Petrosky","year":"2015","journal-title":"Int J Infect Dis"},{"key":"R10-20230711","doi-asserted-by":"crossref","first-page":"e20151968","DOI":"10.1542\/peds.2015-1968","article-title":"Prevalence of HPV After Introduction of the Vaccination Program in the United States","volume":"137","author":"Markowitz","year":"2016","journal-title":"Pediatrics"},{"key":"R11-20230711","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1038\/bjc.2014.198","article-title":"Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16\/18 and closely related HPV types","volume":"110","author":"Kavanagh","year":"2014","journal-title":"Br J Cancer"},{"key":"R12-20230711","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1542\/peds.2011-3587","article-title":"Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction","volume":"130","author":"Kahn","year":"2012","journal-title":"Pediatrics"},{"key":"R13-20230711","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/cid\/civ364","article-title":"Dose-related differences in effectiveness of human papillomavirus vaccination against genital warts: a nationwide study of 550,000 young girls","volume":"61","author":"Blomberg","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R15-20230711","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/jnci\/dju400","article-title":"Performance of self-collected cervical samples in screening for future precancer using human papillomavirus DNA testing","volume":"107","author":"Porras","year":"2015","journal-title":"J Natl Cancer Inst"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006250-201612000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T19:20:33Z","timestamp":1689103233000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006250-201612000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000001760","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}